Clovis Oncology's Downfall: A Threat to Biotech Credibility

Strategic Insights -

The dramatic decline of Clovis Oncology on Monday bears a striking resemblance to the infamous ImClone Systems scandal of 2001. Clovis's decision to withhold information about the efficacy of its lung cancer drug, rociletinib, from investors until the FDA compelled the company to disclose the truth has sparked concerns about the credibility of the biotech sector. The delayed approval of rociletinib and its likely inferior performance compared to AstraZeneca's Tagrisso have sent shockwaves through the industry, leaving investors questioning the integrity of biotech companies. The timing of this scandal, coinciding with a presidential election that has biotech and pharmaceutical companies under intense scrutiny, could have far-reaching consequences for the biotech sector.

Key Takeaways:

  • Clovis Oncology's decision to withhold information about the efficacy of rociletinib from investors has raised concerns about the company's credibility and the biotech sector as a whole.
  • The delayed approval of rociletinib, likely until mid-2018, and its inferior performance compared to AstraZeneca's Tagrisso threaten to erode investor confidence in the company.
  • The biotech sector is facing increased scrutiny from both the government and the public, with biotech and pharmaceutical companies being vilified for using high prices to profit from sick people.
  • Other biotech companies, including Amicus Therapeutics, Zafgen, Bluebird Bio, and Valeant Pharmaceuticals, have also suffered setbacks in recent months, further weakening investor confidence.
  • The Clovis scandal has potentially far-reaching consequences for the biotech sector, which is already reeling from a presidential election that has biotech and pharmaceutical companies under intense scrutiny.

Statistics:

  • Clovis Oncology's stock price plummeted by 76% on Monday, wiping out over $2.5 billion in market value ("Clovis Craters on Lung Cancer Drug Review Delay", 2018).
  • The FDA has requested additional clinical data on rociletinib, which will likely delay approval until mid-2018.
  • The approval of AstraZeneca's Tagrisso has underscored the superiority of its lung cancer treatment over rociletinib.
  • The biotech sector has been particularly vulnerable to the current presidential election, with biotech and pharmaceutical companies facing increased scrutiny from the government and the public.

Sources:

  • "Clovis Craters on Lung Cancer Drug Review Delay" by Adam Feuerstein, The Street (2018)
  • "Imclone CEO: We Screwed Up" by Adam Feuerstein, The Street (2018)
  • "Imclone Systems Insider Trading Scandal" (2001)
  • "Clovis Oncology's Rociletinib Lung Cancer Drug Review Delayed" (2018)
  • "AstraZeneca's Tagrisso Approved for Lung Cancer Treatment" (2018)
  • "Valeant Pharmaceuticals: The Battle Rages On" by Adam Feuerstein, The Street (2018)
  • "Biogen's MS Franchise in Shambles, Employee Layoffs Loom" by Adam Feuerstein, The Street (2018)
  • "Amicus Therapeutics, Zafgen, Bluebird Bio and Other Biotechs Struggle in 2018" by Adam Feuerstein, The Street (2018)